Back to top
more

Embecta Corp. (EMBC)

(Real Time Quote from BATS)

$10.00 USD

10.00
112,559

+0.04 (0.40%)

Updated Aug 4, 2025 01:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Embecta Corp. (EMBC) Tops Q2 Earnings Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 6.06% and 2.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Solventum (SOLV) delivered earnings and revenue surprises of 12.61% and 3.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 44.44% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pfizer (PFE) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 31.25% and 1.52%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC

by Zacks Equity Research

Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.

Urmimala Biswas headshot

4 MedTech Stocks Poised to Thrive Under Second Trump Presidency

by Urmimala Biswas

Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR.

Zacks Equity Research

The Zacks Analyst Blog Highlights Doximity, BrightSpring Health Services and Embecta

by Zacks Equity Research

Doximity, BrightSpring Health Services and Embecta are part of the Zacks top Analyst Blog.

Vasundhara Sawalka headshot

3 Stocks Trading Near 52-Week High With Room to Rise Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like EMBC, NFG and REVG are seeing price strength and the momentum is likely to continue.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy to Counter Labor Shortage Woes

by Urmimala Biswas

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most. However, healthcare staffing shortage is leading to an increase in labor wages.

Zacks Equity Research

Here's Why You Should Add Ensign Group Stock to Your Portfolio Now

by Zacks Equity Research

ENSG should benefit from expanding facilities and growing footprint, leading to higher service revenues in the future.

Zacks Equity Research

Zacks.com featured highlights include The Gap, Embecta, Blue Bird and ZIM Integrated Shipping Services

by Zacks Equity Research

The Gap, Embecta, Blue Bird and ZIM Integrated Shipping Services are part of the Zacks Screen of the Week article.

Urmimala Biswas headshot

4 Best-Bargain PEG Stocks That Value Investors Love

by Urmimala Biswas

Here are four stocks that fit our screening criteria. These are GAP, EMBC, BLBD and ZIM.

Zacks Equity Research

Here Is Why Bargain Hunters Would Love Fast-paced Mover Embecta Corp. (EMBC)

by Zacks Equity Research

Embecta Corp. (EMBC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

New Strong Buy Stocks for December 2nd

by Zacks Equity Research

EMBC, TOST, MNDY, NTRS and MANU have been added to the Zacks Rank #1 (Strong Buy) List on December 2, 2024.

Zacks Equity Research

Best Value Stocks to Buy for December 2nd

by Zacks Equity Research

EMBC, BLBD and ENVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 2, 2024.

Zacks Equity Research

Best Income Stocks to Buy for December 2nd

by Zacks Equity Research

CTBI and EMBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 2, 2024.

Zacks Equity Research

Embecta Corp. (EMBC) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Embecta Corp. (EMBC) delivered earnings and revenue surprises of 12.50% and 2.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aspira (AWH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aspira (AWH) delivered earnings and revenue surprises of 17.86% and 13.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in HealthEquity (HQY): Can Its 3.5% Jump Turn into More Strength?

by Zacks Equity Research

HealthEquity (HQY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -54.55% and 68.84%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -30% and 1.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DocGo Inc. (DCGO) Tops Q3 Earnings Estimates

by Zacks Equity Research

Motion Acquisition (DCGO) delivered earnings and revenue surprises of 25% and 0.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cencora (COR) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 4.05% and 1.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Premier, Inc. (PINC) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Premier (PINC) delivered earnings and revenue surprises of 30.77% and 7.79%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of 6.25% and 2.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?